Risk factors associated with loco-regional failure after surgical resection in patients with resectable pancreatic cancer

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  Kim, Hyun Ju ^a   Lee, Woo Jung ^a   Kang, Chang Moo ^a   Hwang, Ho Kyoung ^a   Bang, Seung Min ^a   Song, Si Young ^a   Seong, Jinsil ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; GEMCITABINE;

ADJUVANT RADIOTHERAPY; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FAILURE FREE SURVIVAL; FEMALE; HUMAN; LABORATORY TEST; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PANCREAS CANCER; PANCREATICODUODENECTOMY; PERINEURAL INVASION; PHYSICAL EXAMINATION; PREOPERATIVE EVALUATION; PROGRESSION FREE SURVIVAL; RISK FACTOR; VERY ELDERLY; DISEASE FREE SURVIVAL; MIDDLE AGED; PANCREATIC NEOPLASMS; PATHOLOGY; PROGNOSIS; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PANCREATIC NEOPLASMS; PROGNOSIS; RISK FACTORS;

EID: 84976568538     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0157196     Document Type: Article

References (27)

1. Annual report on the cause of death statistics. 2012.
2. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg. 1993; 165: 68-72; discussion 72-63. PMID: 8380315
3. Nitecki SS, Sarr MG, Colby TV, van Heerden JA. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg. 1995; 221: 59-66. PMID: 7826162
4. Brennan MF, Moccia RD, Klimstra D. Management of adenocarcinoma of the body and tail of the pancreas. Ann Surg. 1996; 223: 506-511; discussion 511-502. PMID: 8651741
5. Salem AI, Alfi M, Winslow E, Cho CS, Weber SM. Has survival following pancreaticoduodenectomy for pancreas adenocarcinoma improved over time? J Surg Oncol. 2015; 112: 643-649. doi: 10.1002/jso. 24048 PMID: 26388048
6. Griffin JF, Smalley SR, Jewell W, Paradelo JC, Reymond RD, Hassanein RE, et al. Patterns of failure after curative resection of pancreatic carcinoma. Cancer. 1990; 66: 56-61. PMID: 2354408
7. Westerdahl J, Andren-Sandberg A, Ihse I. Recurrence of exocrine pancreatic cancer-local or hepatic? Hepatogastroenterology. 1993; 40: 384-387. PMID: 8406311
8. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985; 120: 899-903. PMID: 4015380
9. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer. 1987; 59: 2006-2010. PMID: 3567862
10. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999; 230: 776-782; discussion 782-774. PMID: 10615932
11. Smeenk HG, van Eijck CH, Hop WC, Erdmann J, Tran KC, Debois M, et al. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann Surg. 2007; 246: 734-740. PMID: 17968163
12. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001; 358: 1576-1585. PMID: 11716884
13. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004; 350: 1200-1210. PMID: 15028824
14. National Comprehensive Cancer Network (NCCN). Available: http://www.nccn.org/professionals/ physician-gls/pdf/pancreatic.pdf.
15. Asiyanbola B, Gleisner A, Herman JM, Choti MA, Wolfgang CL, Swartz M, et al. Determining pattern of recurrence following pancreaticoduodenectomy and adjuvant 5-flurouracil-based chemoradiation therapy: effect of number of metastatic lymph nodes and lymph node ratio. J Gastrointest Surg. 2009; 13: 752-759. doi: 10.1007/s11605-008-0762-x PMID: 19089517
16. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. Jama. 2007; 297: 267-277. PMID: 17227978
17. Choti MA. Adjuvant therapy for pancreatic cancer-the debate continues. N Engl J Med. 2004; 350: 1249-1251. PMID: 15028829
18. Koshy MC, Landry JC, Cavanaugh SX, Fuller CD, Willett CG, Abrams RA, et al. A challenge to the therapeutic nihilism of ESPAC-1. Int J Radiat Oncol Biol Phys. 2005; 61: 965-966. PMID: 15752874
19. Corsini MM, Miller RC, Haddock MG, Donohue JH, Farnell MB, Nagorney DM, et al. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005). J Clin Oncol. 2008; 26: 3511-3516. doi: 10.1200/JCO.2007.15.8782 PMID: 18640932
20. Hsu CC, Herman JM, Corsini MM, Winter JM, Callister MD, Haddock MG, et al. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol. 2010; 17: 981-990. doi: 10.1245/s10434-009-0743-7 PMID: 20087786
21. Yeo CJ, Abrams RA, Grochow LB, Sohn TA, Ord SE, Hruban RH, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg. 1997; 225: 621-633; discussion 633-626. PMID: 9193189
22. Herman JM, Swartz MJ, Hsu CC, Winter J, Pawlik TM, Sugar E, et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol. 2008; 26: 3503-3510. doi: 10.1200/JCO.2007.15.8469 PMID: 18640931
23. Rutter CE, Park HS, Corso CD, Lester-Coll NH, Mancini BR, Yeboa DN, et al. Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: An analysis of the National Cancer Data Base. Cancer. 2015; 121: 4141-4149. doi: 10. 1002/cncr.29652 PMID: 26280559
24. Lundin J, Roberts PJ, Kuusela P, Haglund C. The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer. Br J Cancer. 1994; 69: 515-519. PMID: 7510116
25. Hallemeier CL, Botros M, Corsini MM, Haddock MG, Gunderson LL, Miller RC. Preoperative CA 19-9 level is an important prognostic factor in patients with pancreatic adenocarcinoma treated with surgical resection and adjuvant concurrent chemoradiotherapy. Am J Clin Oncol. 2011; 34: 567-572. doi: 10. 1097/COC.0b013e3181f946fc PMID: 21150564
26. Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-delCastillo C, Warshaw AL. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol. 2006; 24: 2897-2902. PMID: 16782929
27. Koom WS, Seong J, Kim YB, Pyun HO, Song SY. CA 19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2009; 73: 1148-1154. doi: 10.1016/j.ijrobp.2008.06.1483 PMID: 18760544